LOSE WEIGHT WITH MEDICAL SUPPORT — BUILT FOR MEN
- Your personalised programme is built around medical care, not willpower.
- No generic diets. No guesswork.
- Just science-backed results and expert support.
Find out if you’re eligible
Mounjaro (tirzepatide) is a prescription medicine licensed in the UK for type 2 diabetes and weight management in adults with obesity or overweight with comorbidities. It works as a dual GIP and GLP-1 receptor agonist, improving blood glucose control and promoting weight loss. Endometriosis is a chronic inflammatory condition affecting approximately 1 in 10 women of reproductive age, causing pelvic pain and other debilitating symptoms. Whilst some have speculated whether Mounjaro's metabolic effects might indirectly benefit endometriosis patients with obesity, there is currently no clinical evidence or regulatory approval for this use. This article examines the evidence and clarifies appropriate treatment pathways for endometriosis in the UK.
Quick Answer: Mounjaro (tirzepatide) is not licensed or recommended for endometriosis treatment, and no clinical trials have investigated its use for this condition.
Mounjaro (tirzepatide) is a prescription medicine licensed in the UK for the treatment of type 2 diabetes mellitus and, more recently, for weight management in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with weight-related comorbidities, as an adjunct to reduced-calorie diet and increased physical activity. It is administered as a once-weekly subcutaneous injection and belongs to a class of medications known as dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists.
The mechanism of action of Mounjaro involves mimicking two naturally occurring incretin hormones. GLP-1 receptor activation enhances insulin secretion in response to elevated blood glucose, suppresses glucagon release, slows gastric emptying, and reduces appetite through central nervous system pathways. The additional GIP receptor agonism is thought to complement these effects by further improving insulin sensitivity and enhancing weight loss. Together, these actions lead to improved glycaemic control and weight reduction.
Common adverse effects include gastrointestinal symptoms such as nausea, vomiting, diarrhoea, constipation, and abdominal discomfort, particularly during dose escalation. These effects are generally mild to moderate and tend to diminish over time. More serious but rare risks include pancreatitis, gallbladder disease, and hypoglycaemia (primarily when used with insulin or sulphonylureas). Patients should be counselled about these potential side effects and advised to report persistent abdominal pain or signs of pancreatitis immediately. Tirzepatide should be avoided in patients with severe gastrointestinal disease, and patients should be advised about the risk of dehydration which may lead to renal impairment.
Importantly, tirzepatide delays gastric emptying and can reduce the absorption of oral medications, including oral contraceptives. Women using oral contraceptives should use additional or non-oral contraception for 4 weeks after starting tirzepatide and after each dose increase. Treatment should be stopped at least 1 month before planned pregnancy and is not recommended during pregnancy or breastfeeding.
It is important to note that Mounjaro is not currently licensed for the treatment of endometriosis or any gynaecological condition. Its use is strictly indicated for metabolic disorders, and any consideration of off-label use would require careful clinical justification and discussion with a specialist.
Endometriosis is a chronic inflammatory condition affecting approximately 1 in 10 women of reproductive age in the UK. It occurs when tissue similar to the endometrium (the lining of the uterus) grows outside the uterine cavity, commonly on the ovaries, fallopian tubes, pelvic peritoneum, and occasionally on more distant organs. This ectopic endometrial-like tissue responds to hormonal changes during the menstrual cycle, leading to inflammation, scarring, and adhesion formation. While this article refers to women, it's important to note that endometriosis can also affect trans men and non-binary people assigned female at birth.
Common symptoms include chronic pelvic pain, particularly dysmenorrhoea (painful periods), dyspareunia (pain during or after sexual intercourse), and cyclical pain that may worsen around menstruation. Many people also experience subfertility, fatigue, painful bowel movements or urination (especially during menstruation), and heavy menstrual bleeding. The severity of symptoms does not always correlate with the extent of disease visible on imaging or during surgery.
Current evidence-based treatments in the UK, as outlined by NICE guidelines (NG73), include both medical and surgical approaches. First-line medical management typically involves hormonal therapies such as the combined oral contraceptive pill, progestogens (including the levonorgestrel intrauterine system), or GnRH analogues with add-back hormone replacement therapy. These aim to suppress ovulation and reduce endometrial tissue growth. Analgesics, including NSAIDs and paracetamol, are used for pain management.
Diagnostic investigations may include transvaginal ultrasound (particularly useful for identifying endometriomas and some forms of deep disease) and MRI for suspected deep infiltrating endometriosis. While CA125 blood tests may be elevated in endometriosis, they are not diagnostic and have limited value.
When medical management is insufficient or fertility is a concern, surgical intervention may be considered. Laparoscopy serves both diagnostic and therapeutic purposes, allowing for excision or ablation of endometriotic lesions, which can provide symptom relief and improve fertility outcomes in selected cases. For severe or complex disease, referral to a British Society for Gynaecological Endoscopy (BSGE) accredited endometriosis centre is recommended. A multidisciplinary approach involving gynaecologists, pain specialists, physiotherapists, and psychological support is often beneficial for managing this complex condition.
LOSE WEIGHT WITH MEDICAL SUPPORT — BUILT FOR MEN
Find out if you’re eligible
There is currently no official link between Mounjaro (tirzepatide) and the treatment of endometriosis. No clinical trials have investigated tirzepatide specifically for endometriosis management, and it is not licensed or recommended for this indication by the MHRA (Medicines and Healthcare products Regulatory Agency) or NICE. Any discussion of potential benefits remains theoretical and should not be interpreted as clinical guidance.
Some patients and clinicians have speculated whether the weight loss effects of Mounjaro might indirectly benefit women with endometriosis who also have obesity. Obesity is associated with chronic low-grade inflammation and altered hormonal profiles, including increased oestrogen production from adipose tissue, which could theoretically influence endometriosis. However, the evidence on weight loss and endometriosis symptoms is limited and inconsistent; the relationship between body weight and endometriosis severity remains poorly understood across studies.
Furthermore, the gastrointestinal side effects of Mounjaro—including nausea, vomiting, and abdominal pain—could potentially overlap with or exacerbate symptoms experienced by women with endometriosis, particularly those with bowel involvement. This could make symptom assessment more challenging and potentially reduce quality of life during treatment.
Important safety considerations include the fact that tirzepatide has not been studied in pregnant women and is not recommended during pregnancy or breastfeeding. Treatment should be stopped at least 1 month before planned pregnancy and immediately if pregnancy occurs. Women of childbearing potential should use effective contraception during treatment. Notably, tirzepatide can reduce the absorption of oral contraceptives, so additional or non-oral contraception is needed for 4 weeks after starting treatment and after each dose increase. Given that many women with endometriosis are of reproductive age and may be trying to conceive, these represent significant limitations.
Patients should never use Mounjaro off-label for endometriosis without explicit guidance from a specialist, as the risks and benefits have not been established for this indication. Any suspected adverse reactions should be reported via the MHRA Yellow Card Scheme (yellowcard.mhra.gov.uk).
Women experiencing symptoms suggestive of endometriosis should be encouraged to consult their GP for initial assessment. According to NICE guidance (NG73), a clinical diagnosis of endometriosis can be made based on typical symptoms without the need for immediate surgical confirmation, allowing earlier initiation of treatment.
First-line management typically involves a trial of hormonal treatment, even before definitive diagnosis. Options include:
Combined hormonal contraceptives (pills, patches, or vaginal rings) taken continuously or cyclically
Progestogens such as norethisterone, desogestrel, or the levonorgestrel intrauterine system (Mirena)
GnRH analogues (e.g., goserelin, leuprorelin) with add-back HRT to minimise menopausal side effects for longer-term use
These treatments aim to suppress ovulation and reduce the hormonal stimulation of endometriotic tissue. Analgesics including paracetamol and NSAIDs (such as ibuprofen or mefenamic acid) should be offered for pain management.
Investigations in primary care may include pelvic ultrasound, particularly when endometriomas are suspected. MRI may be arranged for suspected deep infiltrating endometriosis, usually via specialist referral.
When medical management fails to provide adequate symptom control, or when fertility is a primary concern, referral to a gynaecologist is appropriate. NICE recommends earlier referral for fertility assessment if subfertility is present or suspected. Laparoscopic surgery to excise or ablate endometriotic lesions may be considered, with the aim of improving pain and fertility outcomes. For severe or complex disease, referral to a BSGE accredited specialist endometriosis centre is recommended.
Complementary approaches that some women find helpful include pelvic physiotherapy, psychological support, dietary modifications, and acupuncture, though evidence for these varies. A holistic, patient-centred approach that addresses physical symptoms, psychological wellbeing, and quality of life is essential.
Patients should seek urgent medical attention if they experience severe or sudden-onset pelvic pain, as this could indicate complications such as ovarian cyst rupture or torsion. Regular follow-up with healthcare professionals ensures treatment remains effective and appropriate for individual needs.
No, Mounjaro (tirzepatide) is not licensed or approved by the MHRA for endometriosis treatment. It is only indicated for type 2 diabetes and weight management in adults with obesity or overweight with comorbidities.
NICE guidance (NG73) recommends hormonal therapies such as the combined oral contraceptive pill, progestogens, or GnRH analogues with add-back HRT as first-line treatment. Analgesics including NSAIDs and paracetamol are used for pain management, and laparoscopic surgery may be considered when medical management is insufficient.
There is no clinical evidence that weight loss from Mounjaro benefits endometriosis symptoms. The relationship between body weight and endometriosis severity remains poorly understood, and tirzepatide has not been studied for this indication.
All medical content on this blog is created based on reputable, evidence-based sources and reviewed regularly for accuracy and relevance. While we strive to keep content up to date with the latest research and clinical guidelines, it is intended for general informational purposes only.
DisclaimerThis content is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional with any medical questions or concerns. Use of the information is at your own risk, and we are not responsible for any consequences resulting from its use.
